"Ozempic Face": Facial Volume Loss from Rapid Weight Loss

"Ozempic face" describes gaunt, hollowed facial appearance (sunken cheeks, temples, periorbital volume loss) following rapid weight loss on GLP-1 agonists (semaglutide, tirzepatide).

Mechanism

  • GLP-1 agonists → ↓ appetite, ↑ satiety, ↓ gastric emptying → significant caloric deficit → rapid fat loss.
  • Facial fat pads (deep and superficial) atrophy disproportionately; skin laxity from reduced dermal collagen/elastin (age-related) fails to retract.
  • Not drug-specific — occurs with any rapid weight loss (bariatric surgery, intensive lifestyle).

Clinical Features

  • Hollowed temples, flattened malar eminences, deepened nasolabial folds
  • Periorbital shadowing, "skeletonized" appearance
  • May appear older than chronological age

Management & Prevention

  • Gradual Weight Loss: 0.5–1% body weight/week; titrate GLP-1 dose slowly.
  • Protein Intake: 1.2–1.6 g/kg/day preserves lean mass including facial muscle.
  • Resistance Training: Maintains structural support.
  • Skin Care: Retinoids, peptides, sunscreen, hydration — supports dermal quality.
  • Fillers (If Desired): HA fillers restore volume; delay until weight stable 3–6 months.
  • Dose Adjustment: Consider lower maintenance dose if facial wasting distressing.

Perspective

Facial changes reflect successful metabolic improvement. Cardiovascular, hepatic, and joint benefits far outweigh aesthetic concerns for most. Discuss with prescribing clinician and dermatologist.

Orthodontics - Related Articles